{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T05:21:18.833346+00:00","company":{"ticker":"CHE","cik":19584,"company_name":"CHEMED CORP"},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"443b7360c5f10436d59930ee37b220dff441c4fe","cik":19584,"ticker":"CHE","company_name":"CHEMED CORP","filed_at":"2026-04-23T23:59:59+00:00","payload":{"eps_text":"GAAP Diluted Earnings-per-Share (EPS) of $4.84","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-04-23","result_type":"reported_results","revenue_text":"$657.5 million"},"claim":"CHEMED CORP reported first quarter ended March 31, 2026 results: revenue $657.5 million, EPS GAAP Diluted Earnings-per-Share (EPS) of $4.84.","evidence_excerpt":"quarter ended March 31, 2026, versus the comparable prior-year period.  Results for Quarter Ended March 31, 2026  Consolidated operating results: · Revenue increased 1.6% to $657.5 million · GAAP Diluted Earnings-per-Share (EPS) of $4.84, a decrease of 0.4% · Adjusted Diluted EPS of $5.65, an increase of 0.4%  VITAS segment operating results: · Net Patient Revenue","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000019584-26-000010","anchor_url":"https://secwatch.observer/filing/0000019584-26-000010#claim-443b7360c5f10436d59930ee37b220dff441c4fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/19584/000001958426000010/0000019584-26-000010-index.htm"},{"fact_type":"debt_financing","fact_key":"adb8a98d1de2014e86728993e02dd28efe739c76","cik":19584,"ticker":"CHE","company_name":"CHEMED CORP","filed_at":"2026-04-13T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2026-04-10","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"secured overnight financing rate (“SOFR”) plus an additional tiered rate","item_codes_triggered":["2.03"],"maturity_text":"five years","principal_text":"$450 million"},"claim":"CHEMED CORP incurred revolving credit of $450 million with JPMorgan Chase Bank, N.A. at secured overnight financing rate (“SOFR”) plus an additional tiered rate maturing five years.","evidence_excerpt":"On April 10, 2026, Chemed Corporation (“Chemed” or \"we\") renewed our $450 million senior secured credit facilities (“Credit Facilities”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000019584-26-000008","anchor_url":"https://secwatch.observer/filing/0000019584-26-000008#claim-adb8a98d1de2014e86728993e02dd28efe739c76","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/19584/000001958426000008/0000019584-26-000008-index.htm"},{"fact_type":"material_agreement","fact_key":"62b2784a537fea97d8f1aeb7bdf6a83b88441a39","cik":19584,"ticker":"CHE","company_name":"CHEMED CORP","filed_at":"2026-04-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Sixth Amended and Restated Credit Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2026-04-10","item_codes_triggered":["1.01"],"value_text":"$450 million"},"claim":"CHEMED CORP entered into Sixth Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. valued at $450 million (effective 2026-04-10).","evidence_excerpt":"On April 10, 2026, Chemed Corporation (“Chemed” or \"we\") renewed our $450 million senior secured credit facilities (“Credit Facilities”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000019584-26-000008","anchor_url":"https://secwatch.observer/filing/0000019584-26-000008#claim-62b2784a537fea97d8f1aeb7bdf6a83b88441a39","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/19584/000001958426000008/0000019584-26-000008-index.htm"},{"fact_type":"earnings_release","fact_key":"507617e5d8456e589b7844294ca38034c3837b7e","cik":19584,"ticker":"CHE","company_name":"CHEMED CORP","filed_at":"2024-04-24T23:59:59+00:00","payload":{"eps_text":"$4.24","guidance_signal":"unknown","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-04-24","result_type":"reported_results","revenue_text":"$589.2 million"},"claim":"CHEMED CORP reported first quarter ended March 31, 2024 results: revenue $589.2 million, EPS $4.24.","evidence_excerpt":"· Revenue increased 5.2% to $589.2 million · GAAP Diluted Earnings-per-Share (EPS) of $4.24, an increase of 18.4% · Adjusted Diluted EPS of $5.20, an increase of 21.5%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001562762-24-000096","anchor_url":"https://secwatch.observer/filing/0001562762-24-000096#claim-507617e5d8456e589b7844294ca38034c3837b7e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000096/0001562762-24-000096-index.htm"},{"fact_type":"ma_transaction","fact_key":"d0a22fc9265d26a789a3310aae13b987b779886c","cik":19584,"ticker":"CHE","company_name":"CHEMED CORP","filed_at":"2024-04-17T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-04-17","consideration_text":"$85 million","counterparty":"Covenant Health and Community Services, Inc., d/b/a Covenant Care","effective_date":"2024-04-17","item_codes_triggered":["2.01"]},"claim":"CHEMED CORP completed an acquisition involving Covenant Health and Community Services, Inc., d/b/a Covenant Care for $85 million (closed 2024-04-17).","evidence_excerpt":"VITAS Healthcare Corporation (“VITAS”), a wholly-owned indirect subsidiary of Chemed, completed its acquisition of substantially all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc., d/b/a Covenant Care, a Florida not for profit corporation (“Covenant”), for $85 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001562762-24-000090","anchor_url":"https://secwatch.observer/filing/0001562762-24-000090#claim-d0a22fc9265d26a789a3310aae13b987b779886c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000090/0001562762-24-000090-index.htm"}]}